$ USD
¥ 人民币
$ USD
€ 欧元
English
简体中文
English
繁体中文
Sign In / Sign up
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Menu
Home page
News
Tumor Information
Tumor Information
Tumor medication
Tumor medication
Drug data
Drug data
Tumor medication
Oncology
renal cell carcinoma
cell tumor
solid tumors
IDH1 mutation
non-small cell lung cancer
neurofibromatosis
liposarcoma
neurofibromatosis
Cachexia
bladder cancer
Common Medications
Common medications
Hematology
Hepatobiliary
chronic disease
Endocrinology
Rare disease drugs
Other medications
insomnia
depression
chronic cough
kidney transplant
Drug Classification
Brand Medicine Search
Brand Medicine Search
日本日医工株式会社
日本盐野义制药
日本杏林制药株式会社
日本株式会社
老挝卢修斯
hormone receptor positive
constipate
heart disease
constipate
depression
日本株式会社
日本田边三菱
英国FuturaMedical制药
日本盐野义制药
日本杏林制药株式会社
Medical Q&A
Medical Q&A
About Us
About Us
Home
News
News
Medical Halo Global Pharmaceutical News_Targeted Drugs_New Anti-Cancer Drugs_Overseas Medical Information_【Medical Halo Global Pharmaceutical】
Which manufacturers produce Zolbetuximab and analysis of the differences between original drugs and generic drugs
2026-02-01 22:25:32
Check Details
Analysis of the role and efficacy of EIKANCE 0.01% atropine sulfate eye drops and its application in the prevention and control of myopia in children
2026-02-01 22:25:32
Check Details
How to buy Pitolisant? Formal channels, prescription procedures and imported drug guide
2026-02-01 22:25:32
Check Details
Complete description of Pretomanid purchase channels, prescription requirements and guide to obtaining drugs from regular pharmacies
2026-02-01 22:25:32
Check Details
What is the name of voclosporin and an introduction to the names and specifications of different brands of drugs on the market?
2026-02-01 22:25:32
Check Details
Ponatinib (ponatinib) Hong Kong version drug information, including indications, specifications and drug purchase channel instructions
2026-02-01 22:25:32
Check Details
Safinamide tablets’ marketing status, approval information and patient access information in China
2026-02-01 22:25:32
Check Details
Efficacy, indications and clinical research summary of Tarlatamab-Imdelltra in the treatment of small cell lung cancer
2026-02-01 22:25:32
Check Details
Telisotuzumab-EMRELIS medication precautions and safety and risk tips for long-term use
2026-02-01 22:25:32
Check Details
Possible reactions after discontinuation of tovorafenib and instructions for medication risks and safe discontinuation protocols
2026-02-01 22:25:32
Check Details
How long does it take for vorasidenib-VORANIGO to take effect and analysis of clinical course of treatment, onset of effect and patient experience
2026-02-01 22:25:32
Check Details
Zongatinib (Zongatinib) mechanism of action, pharmacological effects and scientific principles in tumor treatment
2026-02-01 22:25:32
Check Details
1
2
...
2454
2455
2456
2457
2458
2459
2460
...
10228
10229
Category
Oncology
Hepatobiliary
dermatology
Endocrinology
Hematology
Andrology
Gynecology
Nephrology
Urology
Department of Infectious Diseases
Gastroenterology
Respiratory department
Neurology
Cardiology and Brain Department
ophthalmology
Psychiatry
Immunology Department
orthopedics
Burn Department
相关知识
1
Cemiplimab: A PD-1 Checkpoint Inhibitor for Skin Cancers and Non-Small Cell Lung Cancer
2
Nintedanib: A Multi-Target Antifibrotic Agent for Slowing Pulmonary Fibrosis Progression
3
Capmatinib (Tabrecta): Generational Positioning, Adverse Effect Incidence, and Comprehensive Management
4
Gilteritinib (XOSPATA): Dosing Cycle, Treatment Duration, and Development Background
5
Dabrafenib (TAFINLAR): Indications, Adverse Effect Management, and Dose Modification Guide
6
Adagrasib (Krazati): A Complete Guide to Side-Effect Recognition and Grade-Based Management
7
Tepotinib (TEPMETKO): Complete Dosing, Side-Effect Management, and Discontinuation Guide
8
Valganciclovir (Valcyte) in Post-Transplant CMV Management: A Comprehensive Guide
9
Tivozanib Dosage and Administration: Standard Dosing, Cycle Schedule, and Hepatic Impairment Adjustments
10
Long-Term Anagrelide Use: Common Adverse Effects and Key Monitoring Considerations
11
Resmetirom Indication Clarification: Approved for NASH Fibrosis, Not Hepatitis B Cirrhosis
12
Vemurafenib: Mechanism of Action and Clinical Role in BRAF V600E–Targeted Therapy